DNMT1 and acute myeloid leukemia: DNMT inhibitors (DNMTi), such as decitabine (5-aza-2′-deoxycytidine) and 5-azacytidine have been recently approved for the treatment of MDS, CML, and AML, whereas other DNMTi have entered clinical trials.